The Migraine Disability Assessment (MIDAS) Questionnaire (1-3)

- On how many days in the past 3 months did you miss work or school because of your headaches?
- How many days in the past 3 months was your productivity at work or school reduced by half or more because of your headaches? (Do not include days you counted in question 1 where you missed work or school)
- On how many days in the past 3 months did you not do household work (such as housework, home repairs and maintenance, shopping, caring for children and relatives) because of your headaches?
- How many days in the past 3 months was your productivity in household work reduced by half of more because of your headaches? (Do not include days you counted in question 3 where you did not do household work)
- On how many days in the past 3 months did you miss family, social or leisure activities because of your headaches?

The MIDAS Total score is the sum of the 5 questions above, with 0-5 = little or no disability, 6-10 = mild disability, 11-20 = moderate disability, and ≥21 = severe disability.

Two additional questions assess the number of headache days and severity of headaches:

- On how many days in the past 3 months did you have a headache? (If a headache lasted more than 1 day, count each day)
- On a scale of 0 to 10, on average how painful were these headaches? (where 0 = no pain at all, and 10 = pain as bad as it can be)

References

1. Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. *Cephalalgia* 1999; 19: 107-114.
2. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. *Neurology* 1999; 53 :988-994.
3. Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. *Neurology* 2001; 56: S20-S28.

Supplemental Table 1. Medical History (Safety Population)

Preferred Term,[a] *n* (%)	Lasmiditan 100 mg *N* = 963	Lasmiditan 200 mg *N* = 1015	All Patients *N* = 1978
Seasonal allergy	223 (23.2)	260 (25.6)	483 (24.4)
Depression	215 (22.3)	221 (21.8)	436 (22.0)
Drug hypersensitivity	183 (19.0)	202 (19.9)	385 (19.5)
Anxiety	184 (19.1)	191 (18.8)	375 (19.0)
Hypertension	167 (17.3)	193 (19.0)	360 (18.2)
Hysterectomy[b]	128 (15.6)	143 (16.5)	271 (16.1)
Headache	155 (16.1)	157 (15.5)	312 (15.8)
Gastroesophageal reflux syndrome	145 (15.1)	155 (15.3)	300 (15.2)
Female sterilization[c]	127 (15.5)	130 (15.0)	257 (15.2)
Asthma	127 (13.2)	134 (13.2)	261 (13.2)
Insomnia	122 (12.7)	119 (11.7)	241 (12.2)
Back pain	109 (11.3)	130 (12.8)	239 (12.1)
Postmenopause[b]	96 (11.7)	91 (10.5)	187 (11.1)
Obesity	106 (11.0)	111 (10.9)	217 (11.0)

Abbreviation: MedDRA: Medical Dictionary for Regulatory Activities.

Reported by ≥10% of patients in either treatment group.
[a] Medical history coded using MedDRA Version 21.0.
[b] Percentages calculated using the number of women as denominator: *n* = 822 for 100 mg; *n* = 866 for 200 mg; *n* = 1688 overall.

Supplemental Table 2. Frequently Reported Treatment-Emergent Adverse Events by Migraine Attack in Patients Who Treated ≥5 Attacks (Safety Population)

TEAE, *n* (%)[a,b]	Lasmiditan 100 mg (*N* = 560)					Lasmiditan 200 mg (*N* = 566)				
	Migraine Attack					Migraine Attack				
	#1	#2	#3	#4	#5	#1	#2	#3	#4	#5
Dizziness	41 (7.3)	29 (5.2)	26 (4.6)	22 (3.9)	21 (3.8)	53 (9.4)	39 (6.9)	38 (6.7)	33 (5.8)	27 (4.8)
Somnolence	25 (4.5)	14 (2.5)	14 (2.5)	6 (1.1)	6 (1.1)	37 (6.5)	18 (3.2)	11 (1.9)	13 (2.3)	10 (1.8)
Paresthesia	10 (1.8)	3 (0.5)	7 (1.3)	1 (0.2)	2 (0.4)	27 (4.8)	17 (3.0)	18 (3.2)	13 (2.3)	16 (2.8)
Fatigue	15 (2.7)	8 (1.4)	10 (1.8)	7 (1.3)	4 (0.7)	16 (2.8)	14 (2.5)	12 (2.1)	9 (1.6)	7 (1.2)
Nausea	5 (0.9)	2 (0.4)	1 (0.2)	1 (0.2)	0	12 (2.1)	2 (0.4)	3 (0.5)	4 (0.7)	6 (1.1)
Asthenia	6 (1.1)	2 (0.4)	3 (0.5)	4 (0.7)	3 (0.5)	6 (1.1)	3 (0.5)	4 (0.7)	2 (0.4)	3 (0.5)
Hypoesthesia	3 (0.5)	1 (0.2)	0	1 (0.2)	1 (0.2)	4 (0.7)	0	3 (0.5)	2 (0.4)	3 (0.5)
Vertigo	3 (0.5)	2 (0.4)	2 (0.4)	1 (0.2)	1 (0.2)	4 (0.7)	2 (0.4)	4 (0.7)	3 (0.5)	1 (0.2)
Lethargy	3 (0.5)	1 (0.2)	2 (0.4)	2 (0.4)	5 (0.9)	3 (0.5)	6 (1.1)	5 (0.9)	4 (0.7)	3 (0.5)

Abbreviations: AE: adverse event; MedDRA: Medical Dictionary for Regulatory Activities; TEAE: treatment-emergent adverse event.

[a] An AE that occurred or worsened within 48 hours after the last dose (either the first or the second dose) of lasmiditan was considered treatment emergent.
[b] AEs were coded using MedDRA Version 21.0. Patients are counted only once within each preferred term.